Buyvalenko U V, Pokrovskaya E V
Endocrinology Research Centre.
Probl Endokrinol (Mosk). 2022 Jan 20;68(2):66-71. doi: 10.14341/probl12835.
The gut microbiome is the largest microbial habitat in the human body. The main functions include obtaining energy from complex food fibers, maturation and formation of the immune system, intestinal angiogenesis, restoration of epithelial damage to the intestine, development of the nervous system, protection against pathogens, etc. It is also known that a number of drugs can cause changes in the composition of the intestinal microflora, and intestinal bacteria, in turn, produce a number of enzymes and metabolites that can chemically change the structure of drugs, leading to more side effects, and in some cases to positive changes. In this review we present current evidence supporting the effects of microbiota in host-drug interactions, in particular, the reciprocal effects of gut microbiota and oral hypoglycemic drugs on each other. Gaining and evaluating knowledge in this area will help pave the way for the development of new microbiota-based strategies that can be used in the future to improve treatment outcomes for type 2 diabetes mellitus (T2D).
肠道微生物群是人体最大的微生物栖息地。其主要功能包括从复杂的食物纤维中获取能量、免疫系统的成熟与形成、肠道血管生成、肠道上皮损伤的修复、神经系统的发育、抵御病原体等。还已知许多药物会导致肠道微生物群组成的变化,而肠道细菌反过来会产生一些酶和代谢物,这些酶和代谢物可通过化学方式改变药物结构,导致更多副作用,在某些情况下也会产生积极变化。在本综述中,我们展示了支持微生物群在宿主 - 药物相互作用中作用的现有证据,特别是肠道微生物群与口服降糖药相互之间的影响。在这一领域获取和评估知识将有助于为未来可用于改善2型糖尿病(T2D)治疗效果的基于微生物群的新策略的开发铺平道路。